secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2022-01-26T23:59:59+00:00
Accession:  0001193125-22-017722
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex reports 2 complete responses in first 3 patients in Phase 1b KEYNOTE-B84 study for HNSCC
--------------------------------------------------------------------------------

- Two of three patients in Phase 1b safety segment achieved complete responses per RECIST v1.1.
- Both responders had low PD-L1 expression (CPS<20); HPV-negative status.
- Third patient had clinical progression and withdrew before week 9; SAEs attributed to pre-existing condition.
- Expansion phase now open; will enroll up to 62 additional patients across 18 US sites.
- Data safety monitoring board confirmed pepinemab (20 mg/kg Q3W) + KEYTRUDA (200 mg Q3W) well-tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522017722/0001193125-22-017722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522017722/d252591d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-017722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer